{"id":"W2586480138","doi":"10.1016/s1474-4422(17)30007-8","title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","year":2017,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame","funders":"NIH Clinical Center; National Health and Medical Research Council; Canadian Institutes of Health Research; Novartis Pharma; EMD Serono; H. Lundbeck A/S; Sanofi Genzyme; Isfahan University of Medical Sciences; Multiple Sclerosis Society; Celgene; Fondazione Italiana Sclerosi Multipla; Biogen; York University; Università degli Studi di Firenze; Multiple Sclerosis Society of Canada; Univerzita Karlova v Praze; Diabetes-Stiftung; NYU Langone Medical Center; Jewish General Hospital; National Institute for Health and Care Research; Medical Research Council; Teva Pharmaceutical Industries; GlaxoSmithKline; Rosetrees Trust; Sanofi","keywords":"Natalizumab; Fingolimod; Multiple sclerosis; Alemtuzumab; Medicine; Relapsing remitting; Cohort; Interferon beta; Interferon beta-1a; Interferon beta-1b; Internal medicine; Oncology; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008500998,0.0002197464,0.001028794,0.00009737512,0.0002751839,0.00003096949,0.0003000066,0.0000580083,0.000003088585],"category_scores_gemma":[0.0005288522,0.000130123,0.00004345812,0.00007392427,0.0005752328,0.00006826125,0.0003382798,0.0003273097,0.000001722999],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007105049,"about_ca_system_score_gemma":0.00003967771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002401025,"about_ca_topic_score_gemma":0.002150791,"domain_scores_codex":[0.997982,0.0006398121,0.000274704,0.0004557364,0.0002370062,0.0004107594],"domain_scores_gemma":[0.9975722,0.001074393,0.0002068898,0.001005139,0.0000808828,0.00006046376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01118888,0.0004368046,0.9803119,0.000131005,0.0002977041,0.00005389891,0.001131897,0.00004893521,0.00458701,0.000008889308,0.00001167248,0.001791371],"study_design_scores_gemma":[0.01600788,0.004881292,0.9756077,0.000314029,0.0001025021,0.00004171758,0.0001532145,0.001402947,0.001363577,0.000006590461,0.00002485665,0.00009368707],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961123,0.0002272768,0.000008123958,0.001093834,0.00006695055,0.002082188,0.0000145881,0.00003105127,0.0003636448],"genre_scores_gemma":[0.9991904,0.0003069807,0.00004106461,0.00005085153,0.00007222715,0.000296588,0.000005468958,0.00002520806,0.00001119522],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004819003,"threshold_uncertainty_score":0.5306263,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09599620926818118,"score_gpt":0.3348241183615268,"score_spread":0.2388279090933456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}